Cleveland BioLabs (NASDAQ:CBLI) Stock Price Crosses Above Two Hundred Day Moving Average of $1.50

Share on StockTwits

Cleveland BioLabs, Inc. (NASDAQ:CBLI)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.50 and traded as high as $1.04. Cleveland BioLabs shares last traded at $1.04, with a volume of 1,391 shares trading hands.

Separately, ValuEngine raised Cleveland BioLabs from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

The firm has a 50 day moving average price of $1.36 and a 200-day moving average price of $1.50.

Cleveland BioLabs (NASDAQ:CBLI) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.28 million during the quarter. Cleveland BioLabs had a negative net margin of 304.43% and a negative return on equity of 96.01%.

About Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.

Further Reading: Short Selling Stocks, A Beginner’s Guide

Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.